Starting from these considerations, our study was undertaken to investigate the in vitro therapeutic potential of combining selinexor and a BsAb that is able to retarget peripheral blood lymphocytes (PBLs) to increase the killing of TRAIL-R2-positive TNBC cancer cells. The gene discussed is TNFRSF10B; the disease is cancer.